Q4250 HCPCS Code Description and Billing Reference | NextGen Biologics

Q4250 HCPCS Code: Description, Billing, and Reimbursement for AmnioAMP-MP

Billing staff searching for the Q4250 code descriptor need three things fast: what the code covers, which product it maps to, and how to pair it with the correct application CPT on a clean claim. This page is a focused code reference. For the comprehensive coding environment — including withdrawn LCDs, evidence behind amniotic membrane allografts, and the full CPT/HCPCS/ICD-10 framework — see our reimbursement coding guide.

Q4250 Code Description

HCPCS Level II code Q4250 identifies AmnioAMP-MP, a dehydrated human amniotic membrane (DDHAM) skin substitute graft, billed per square centimeter. CMS established the code effective October 1, 2020, through the HCPCS application process for drugs and biologicals [2]. The code is product-specific: it does not apply to other amniotic membrane products, even those with similar formulations or indications.

The official descriptor classifies Q4250 as a temporary Q-code — the category CMS uses for products that do not yet have a permanent national code but meet the criteria for separate billing under the Physician Fee Schedule or Hospital Outpatient Prospective Payment System. Q-codes are reviewed and updated quarterly, so billing teams should confirm the current code assignment before each cycle through the CMS HCPCS Level II code file.

Product Mapping: AmnioAMP-MP

AmnioAMP-MP is a decellularized dehydrated human amniotic membrane (DDHAM), E-Beam sterilized (SAL 10⁻⁶), supplied as a dry sheet stored at ambient temperature — eliminating cold-chain logistics from the billing and inventory workflow. Sizes range from 2×2 cm to 12×21 cm 3]. For the clinical application protocol, see our [in-office AmnioAMP-MP application guide.

A common billing error is assuming that one amniotic membrane product's Q-code applies to another. It does not. Rampart DL Matrix maps to Q4347 — not Q4250. Each product carries its own HCPCS assignment. Misapplying a product-specific code is one of the most frequent causes of claim denial and audit findings in wound care billing.

Pairing Q4250 with CPT 15271–15278 Application Codes

Q4250 reports the product. The application procedure is reported separately using CPT codes 15271–15278, which describe the clinician's work of applying a skin substitute graft to a defined wound area at a specific anatomic site [3].

The code family splits by anatomy and wound size:

| Code Range | Anatomic Site | Structure | |---|---|---| | CPT 15271–15272 | Trunk, arms, legs | 15271 = first 25 cm²; 15272 = each additional 25 cm² | | CPT 15273–15274 | Trunk, arms, legs (wounds >100 cm²) | 15273 = first 100 cm²; 15274 = each additional 100 cm² | | CPT 15275–15276 | Face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, digits | 15275 = first 25 cm²; 15276 = each additional 25 cm² | | CPT 15277–15278 | Same sites as above (wounds >100 cm²) | 15277 = first 100 cm²; 15278 = each additional 100 cm² |

On a single claim, the product line (Q4250, units = cm² applied) and the procedure line (CPT from the table above) must agree on total treated surface area and anatomic site. The units billed for Q4250 should equal the total square centimeters of AmnioAMP-MP applied to the wound — not the package size. If a sheet is opened but only partially applied, the billable units depend on payer wastage policy.

Medicare Flat-Rate Reimbursement

Effective January 1, 2026, CMS replaced the prior average-sales-price-plus-6% methodology with a single national flat rate of approximately $127.14 per square centimeter for non-BLA skin substitute products furnished in physician offices, hospital outpatient departments, and ambulatory surgical centers [1]. Under this rule, products like AmnioAMP-MP are classified as incident-to supplies. The application procedure (CPT 15271–15278) is reimbursed separately under the Physician Fee Schedule professional component.

What this means for billing staff: the reimbursement per unit of Q4250 is approximately $127.14, regardless of acquisition cost. For a procurement-level cost analysis framework built around this rate, see our wound biologics procurement buyer's guide.

Documentation Requirements

A defensible Q4250 claim connects the product, the procedure, the wound, and the medical necessity in a single clinical record. At minimum, document:

- Wound measurements — pre-debridement and post-debridement (length × width in cm), with total treated surface area calculated - Product details — name, lot number, expiration, size opened, area applied (including discarded amount if payer policy requires wastage documentation) - Anatomic site — drives CPT code selection from the 15271–15278 range - Medical necessity — ulcer etiology, duration, failed standard care, offloading or compression plan, vascular assessment, infection status - ICD-10-CM diagnosis codes — ulcer type, site, laterality, severity, comorbidities such as diabetes

Discrepancies between documented wound size and billed units are a primary trigger for post-payment audit recoupment.

Common Billing Errors

1. Wrong product code. Assuming Q4250 covers all amniotic membrane products. Each product has its own Q-code. Verify the product-to-code mapping for every item in your inventory against the current CMS HCPCS file. 2. Units mismatch. Billing Q4250 units equal to the package size rather than the applied area. Units must reflect total square centimeters applied to the wound, consistent with the CPT application code. 3. Missing CPT pairing. Submitting Q4250 without the corresponding 15271–15278 application code, or vice versa. The product and procedure codes are interdependent — one without the other will trigger an edit or denial. 4. Insufficient medical-necessity documentation. Repeated applications without documented wound response or rationale for continuation weaken audit defensibility. Record serial measurements and clinical reasoning at each visit. 5. Expired code assumptions. HCPCS Q-codes are updated quarterly. A code active last quarter may be revised, consolidated, or retired. Check the current file before each billing cycle.

Related Resources

- Reimbursement Coding for Amniotic Membrane Allografts: Comprehensive Guide — Canonical reference for the full coding environment, LCD status, and multi-code framework - Wound Biologics Procurement Buyer's Guide — HCPCS code reference table across all wound biologic categories - Wound Care Products Comparison — Side-by-side product specs and HCPCS codes - In-Office AmnioAMP-MP Application Protocol — Step-by-step clinical application workflow

---

References

1. Centers for Medicare & Medicaid Services. Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F). Published October 31, 2025. 2. Centers for Medicare & Medicaid Services. 2020 HCPCS Application Summary, Biannual 2, Drugs and Biologicals. Final decision establishing Q4250 for AmnioAMP-MP, effective October 1, 2020. 3. American Medical Association. CPT Professional Edition. Codes 15271–15278: Application of skin substitute grafts. CMS HCPCS Level II Code File, Q4250 descriptor and product crosswalk.